In clinical trials, RINVOQ (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 521-4 A greater.
Separating Fact From Fallacy in Celiac Disease clinicaladvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaladvisor.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating.
Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today positive preliminary results of its ongoing first-in-human trial. GT-30 is a phase I/II trial of personalized vaccine, GNOS-PV02, in combination with plasmid pIL-12 and pembrolizumab in patients in second line advanced hepatocellular carcinoma (HCC).